Pharmaceutics, Volume 17, Issue 10
2025 October - 123 articles
Cover Story: Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis despite multimodal therapy. Small interfering RNA (siRNA) therapeutics can silence oncogenic genes, but efficient and tumor-specific delivery remains challenging. Lipid nanoparticles (LNPs) are promising siRNA carriers; however, conventional antibody conjugation can disrupt antigen binding and complicate manufacturing. This study presents an orientation-controlled, Fc-binding peptide (FcBP)-mediated post-insertion method enabling site-specific antibody modification of LNPs while preserving physicochemical integrity and binding activity. Anti–PD-L1–FcBP–LNPs achieved enhanced VEGF silencing and tumor suppression in GBM models, offering a versatile and translational platform for targeted RNA therapeutics. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
